14-hydroxyclarithromycin (BioDeep_00000054426)

   

human metabolite Endogenous blood metabolite


代谢物信息卡片


(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-12,13-dihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-14-(1-hydroxyethyl)-7-methoxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione

化学式: C38H69NO14 (763.4717813999999)
中文名称:
谱图信息: 最多检出来源 Homo sapiens(blood) 83.33%

分子结构信息

SMILES: CC1CC(C(C(O1)OC2C(C(C(C(=O)OC(C(C(C(C(=O)C(CC2(C)OC)C)C)O)(C)O)C(C)O)C)OC3CC(C(C(O3)C)O)(C)OC)C)O)N(C)C
InChI: InChI=1S/C38H69NO14/c1-18-16-37(9,48-14)32(53-35-28(42)25(39(11)12)15-19(2)49-35)21(4)29(51-26-17-36(8,47-13)31(44)24(7)50-26)22(5)34(45)52-33(23(6)40)38(10,46)30(43)20(3)27(18)41/h18-26,28-33,35,40,42-44,46H,15-17H2,1-14H3/t18-,19-,20+,21+,22-,23?,24+,25+,26+,28-,29+,30-,31+,32-,33-,35+,36-,37-,38+/m1/s1

描述信息

14-hydroxyclarithromycin is a metabolite of clarithromycin. Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydia pneumoniae or TWAR), skin and skin structure infections. In addition, it is sometimes used to treat Legionellosis, Helicobacter pylori, and lyme disease. (Wikipedia)

同义名列表

7 个代谢物同义名

(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-12,13-dihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-14-(1-hydroxyethyl)-7-methoxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione; 14-Hydroxyclarithromycin, (14S)-isomer; 14-Hydroxyclarithromycin, (14R)-isomer; 14-Hydroxy-6-0-methylerthromycin a; 14-Hydroxy-6-O-methylerythromycin; 14-hydroxyclarithromycin; 14-OH-Clarithromycin



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • D H Vu, R A Koster, A M A Wessels, B Greijdanus, J W C Alffenaar, D R A Uges. Troubleshooting carry-over of LC-MS/MS method for rifampicin, clarithromycin and metabolites in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2013 Feb; 917-918(?):1-4. doi: 10.1016/j.jchromb.2012.12.023. [PMID: 23353809]
  • Jette Peters, Karen Eggers, Stefan Oswald, Wiebke Block, Dieter Lütjohann, Marc Lämmer, Monica Venner, Werner Siegmund. Clarithromycin is absorbed by an intestinal uptake mechanism that is sensitive to major inhibition by rifampicin: results of a short-term drug interaction study in foals. Drug metabolism and disposition: the biological fate of chemicals. 2012 Mar; 40(3):522-8. doi: 10.1124/dmd.111.042267. [PMID: 22170330]
  • Jette Peters, Wiebke Block, Stefan Oswald, Johanna Freyer, Markus Grube, Heyo K Kroemer, Marc Lämmer, Dieter Lütjohann, Monica Venner, Werner Siegmund. Oral absorption of clarithromycin is nearly abolished by chronic comedication of rifampicin in foals. Drug metabolism and disposition: the biological fate of chemicals. 2011 Sep; 39(9):1643-9. doi: 10.1124/dmd.111.039206. [PMID: 21690264]
  • Stefan Oswald, Jette Peters, Monica Venner, Werner Siegmund. LC-MS/MS method for the simultaneous determination of clarithromycin, rifampicin and their main metabolites in horse plasma, epithelial lining fluid and broncho-alveolar cells. Journal of pharmaceutical and biomedical analysis. 2011 Apr; 55(1):194-201. doi: 10.1016/j.jpba.2011.01.019. [PMID: 21310577]
  • Femke de Velde, Jan-Willem C Alffenaar, A Mireille A Wessels, Ben Greijdanus, Donald R A Uges. Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2009 Jun; 877(18-19):1771-7. doi: 10.1016/j.jchromb.2009.04.038. [PMID: 19457725]
  • Xiangrong Zhang, Meijuan Zou, Sanming Li, Xiaoyan Chen, Dafang Zhong. Bioavailability of clarithromycin cyclodextrin ternary complexes upon oral administration to healthy beagle dogs. Drug development and industrial pharmacy. 2008 Oct; 34(10):1048-53. doi: 10.1080/03639040801937474. [PMID: 18608469]
  • Vanitha J Sekar, Sabrina Spinosa-Guzman, Els De Paepe, Martine De Pauw, Tony Vangeneugden, Eric Lefebvre, Richard M W Hoetelmans. Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers. Journal of clinical pharmacology. 2008 Jan; 48(1):60-5. doi: 10.1177/0091270007309706. [PMID: 18094220]
  • Olaf Burkhardt, Klaus Borner, Heino Stass, Gerrit Beyer, Markus Allewelt, Carl Erik Nord, Hartmut Lode. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scandinavian journal of infectious diseases. 2002; 34(12):898-903. doi: 10.1080/0036554021000026963. [PMID: 12587622]
  • S J Martin, C G Garvin, C R McBurney, E G Sahloff. The activity of 14-hydroxy clarithromycin, alone and in combination with clarithromycin, against penicillin- and erythromycin-resistant Streptococcus pneumoniae. The Journal of antimicrobial chemotherapy. 2001 May; 47(5):581-7. doi: 10.1093/jac/47.5.581. [PMID: 11328768]
  • F E Lerner, G Caliendo, V Santagada, Santana GSM, Moraes MEA, G De Nucci. Clarithromycin bioequivalence study of two oral formulations in healthy human volunteers. International journal of clinical pharmacology and therapeutics. 2000 Jul; 38(7):345-54. doi: 10.5414/cpp38345. [PMID: 10919343]
  • S E Boruchoff, M G Sturgill, K W Grasing, J R Seibold, J McCrea, G A Winchell, S E Kusma, P J Deutsch. The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin. Clinical pharmacology and therapeutics. 2000 Apr; 67(4):351-9. doi: 10.1067/mcp.2000.105151. [PMID: 10801243]
  • E Offman, F Varin, T Nolan, C D Bayliff, A M Bombassaro, D G McCormack. Oral absorption of clarithromycin in acute illness and during convalescence in patients with community-acquired pneumonia. Chest. 2000 Apr; 117(4):1090-3. doi: 10.1378/chest.117.4.1090. [PMID: 10767245]
  • K W Garey, C A Peloquin, P G Godo, A N Nafziger, G W Amsden. Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. Antimicrobial agents and chemotherapy. 1999 May; 43(5):1152-5. doi: 10.1128/aac.43.5.1152. [PMID: 10223928]
  • G W Amsden, K L Cheng, C A Peloquin, A N Nafziger. Oral cimetidine prolongs clarithromycin absorption. Antimicrobial agents and chemotherapy. 1998 Jul; 42(7):1578-80. doi: 10.1128/aac.42.7.1578. [PMID: 9660986]
  • S J Martin, S L Pendland. Bactericidal activity and postantibiotic effect of clarithromycin and 14-hydroxyclarithromycin, alone and in combination, against Legionella pneumophila. The Journal of antimicrobial chemotherapy. 1998 Jun; 41(6):643-8. doi: 10.1093/jac/41.6.643. [PMID: 9687103]
  • K A Rodvold, M H Gotfried, L H Danziger, R J Servi. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrobial agents and chemotherapy. 1997 Jun; 41(6):1399-402. doi: 10.1128/aac.41.6.1399. [PMID: 9174209]
  • V N Gan, J M McCarty, S Y Chu, R Carr. Penetration of clarithromycin into middle ear fluid of children with acute otitis media. The Pediatric infectious disease journal. 1997 Jan; 16(1):39-43. doi: 10.1097/00006454-199701000-00009. [PMID: 9002099]
  • K J Walker, A J Larsson, R A Zabinski, J C Rotschafer. Evaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model. Antimicrobial agents and chemotherapy. 1994 Sep; 38(9):2003-7. doi: 10.1128/aac.38.9.2003. [PMID: 7811010]
  • D N Fish, M H Gotfried, L H Danziger, K A Rodvold. Penetration of clarithromycin into lung tissues from patients undergoing lung resection. Antimicrobial agents and chemotherapy. 1994 Apr; 38(4):876-8. doi: 10.1128/aac.38.4.876. [PMID: 8031063]
  • K W Tsang, P Roberts, R C Read, F Kees, R Wilson, P J Cole. The concentrations of clarithromycin and its 14-hydroxy metabolite in sputum of patients with bronchiectasis following single dose oral administration. The Journal of antimicrobial chemotherapy. 1994 Feb; 33(2):289-97. doi: 10.1093/jac/33.2.289. [PMID: 8182010]
  • L Sundberg, A Cederberg. Penetration of clarithromycin and its 14-hydroxy metabolite into middle ear effusion in children with secretory otitis media. The Journal of antimicrobial chemotherapy. 1994 Feb; 33(2):299-307. doi: 10.1093/jac/33.2.299. [PMID: 8182011]
  • S Y Chu, G R Granneman, P J Pichotta, J P Decourt, J Girault, J B Fourtillan. Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics. Journal of clinical pharmacology. 1993 May; 33(5):480-5. doi: 10.1002/j.1552-4604.1993.tb04692.x. [PMID: 8331208]
  • S Y Chu, D S Wilson, D R Guay, C Craft. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. Journal of clinical pharmacology. 1992 Nov; 32(11):1045-9. doi: 10.1002/j.1552-4604.1992.tb03809.x. [PMID: 1474166]
  • Y Cohen, C Perronne, C Truffot-Pernot, J Grosset, J L Vilde, J J Pocidalo. Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages. Antimicrobial agents and chemotherapy. 1992 Oct; 36(10):2104-7. doi: 10.1128/aac.36.10.2104. [PMID: 1332586]
  • J P Bédos, E Azoulay-Dupuis, E Vallée, B Veber, J J Pocidalo. Individual efficacy of clarithromycin (A-56268) and its major human metabolite 14-hydroxy clarithromycin (A-62671) in experimental pneumococcal pneumonia in the mouse. The Journal of antimicrobial chemotherapy. 1992 Jun; 29(6):677-85. doi: 10.1093/jac/29.6.677. [PMID: 1387132]
  • W W Hoover, M S Barrett, R N Jones. Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycin. Diagnostic microbiology and infectious disease. 1992 Mar; 15(3):259-66. doi: 10.1016/0732-8893(92)90122-a. [PMID: 1533827]
  • S Chu, Y Park, C Locke, D S Wilson, J C Cavanaugh. Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial. Journal of clinical pharmacology. 1992 Jan; 32(1):32-6. doi: 10.1002/j.1552-4604.1992.tb03784.x. [PMID: 1531484]
  • J W Gu, B E Scully, H C Neu. Bactericidal activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae and streptococcal pathogens. Journal of clinical pharmacology. 1991 Dec; 31(12):1146-50. doi: 10.1002/j.1552-4604.1991.tb03687.x. [PMID: 1837032]
  • S Y Chu, L T Sennello, R C Sonders. Simultaneous determination of clarithromycin and 14(R)-hydroxyclarithromycin in plasma and urine using high-performance liquid chromatography with electrochemical detection. Journal of chromatography. 1991 Nov; 571(1-2):199-208. doi: 10.1016/0378-4347(91)80446-j. [PMID: 1839793]
  • H Dabernat, C Delmas, M Seguy, J B Fourtillan, J Girault, M B Lareng. The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in-vitro and serum bactericidal tests. The Journal of antimicrobial chemotherapy. 1991 Feb; 27 Suppl A(?):19-30. doi: 10.1093/jac/27.suppl_a.19. [PMID: 1827099]
  • D J Hardy, R N Swanson, R A Rode, K Marsh, N L Shipkowitz, J J Clement. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrobial agents and chemotherapy. 1990 Jul; 34(7):1407-13. doi: 10.1128/aac.34.7.1407. [PMID: 2143642]
  • T Adachi, S Morimoto, H Kondoh, T Nagate, Y Watanabe, K Sota. 14-Hydroxy-6-O-methylerythromycins A, active metabolites of 6-O-methylerythromycin A in human. The Journal of antibiotics. 1988 Jul; 41(7):966-75. doi: 10.7164/antibiotics.41.966. [PMID: 2971033]
  • P B Fernandes, N Ramer, R A Rode, L Freiberg. Bioassay for A-56268 (TE-031) and identification of its major metabolite, 14-hydroxy-6-O-methyl erythromycin. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 1988 Feb; 7(1):73-6. doi: 10.1007/bf01962181. [PMID: 2967754]